Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT03261739 is registered in ClinicalTrials.gov with Bird Rock Bio, Inc. as lead sponsor.

NCT NCT03261739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03261739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Lead sponsor
Bird Rock Bio, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 28, 2017
Completion date
August 24, 2018
Enrollment
84 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

nafld